AU2002243204A1 - Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs - Google Patents

Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs

Info

Publication number
AU2002243204A1
AU2002243204A1 AU2002243204A AU4320402A AU2002243204A1 AU 2002243204 A1 AU2002243204 A1 AU 2002243204A1 AU 2002243204 A AU2002243204 A AU 2002243204A AU 4320402 A AU4320402 A AU 4320402A AU 2002243204 A1 AU2002243204 A1 AU 2002243204A1
Authority
AU
Australia
Prior art keywords
bile
drugs
acid derived
oral absorption
derived compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002243204A
Inventor
Kenneth C. Cundy
Mark A. Gallop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XenoPort Inc
Original Assignee
XenoPort Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XenoPort Inc filed Critical XenoPort Inc
Publication of AU2002243204A1 publication Critical patent/AU2002243204A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2002243204A 2000-10-06 2001-10-05 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs Abandoned AU2002243204A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23875800P 2000-10-06 2000-10-06
US60/238,758 2000-10-06
PCT/US2001/042612 WO2002044324A2 (en) 2000-10-06 2001-10-05 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs

Publications (1)

Publication Number Publication Date
AU2002243204A1 true AU2002243204A1 (en) 2002-06-11

Family

ID=22899179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002243204A Abandoned AU2002243204A1 (en) 2000-10-06 2001-10-05 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs

Country Status (4)

Country Link
US (2) US7144877B2 (en)
EP (1) EP1358200A4 (en)
AU (1) AU2002243204A1 (en)
WO (3) WO2002044324A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098999A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
AU2002243204A1 (en) * 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US6992076B2 (en) * 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1361847A2 (en) * 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US20030212051A1 (en) * 2001-04-06 2003-11-13 Polli James E Bile acid containing prodrugs with enhanced bioavailabilty
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR20090121404A (en) * 2001-06-11 2009-11-25 제노포트 인코포레이티드 Prodrugs of gaba analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7183259B2 (en) 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
CA2789993C (en) 2003-04-11 2016-02-16 Cargill, Incorporated Pellet systems for preparing beverages
WO2005010011A2 (en) 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
US7700652B2 (en) 2003-09-11 2010-04-20 Xenoport, Inc. Treating urinary incontinence using prodrugs of GABA analogs
AU2004274002B2 (en) 2003-09-17 2011-04-28 Arbor Pharmaceuticals, Llc Treating or preventing restless legs syndrome using prodrugs of GABA analogs
SG147437A1 (en) 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
EP1765403A4 (en) * 2004-05-10 2011-03-30 Univ Utah Res Found Combined active and passive targeting of biologically active agents
US20060003361A1 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. SMVT transporters expressed in cancer cells
CN101023056B (en) * 2004-06-04 2011-05-25 克塞诺波特公司 Levodopa prodrugs, and compositions and uses thereof
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
CN101068538A (en) 2004-11-04 2007-11-07 什诺波特有限公司 Gaba analog prodrug sustained release oral dosage forms
EP1959948B1 (en) * 2005-12-05 2012-07-18 XenoPort, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
JP2011502953A (en) 2006-12-21 2011-01-27 ゼノポート，インコーポレーテッド Prodrugs, compositions and methods of use of dimethyl substituted levodopa diesters
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
JP5651009B2 (en) 2007-05-09 2015-01-07 ソウッド ヘルスケア エルエルシー Therapeutic compounds
KR20100017435A (en) 2007-05-09 2010-02-16 파마코포어, 인크. Therapeutic compounds
EP2584027B1 (en) 2007-10-11 2015-12-30 Promega Corporation Cleavable surfactants
CN102177172A (en) * 2008-07-02 2011-09-07 埃迪尼克斯医药公司 Compounds and pharmaceutical compositions for the treatment of viral infections
WO2010047775A2 (en) 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US8168756B2 (en) 2008-10-24 2012-05-01 Ark Diagnostics, Inc. Levetiracetam immunoassays
JP2013520521A (en) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド Pharmaceutical composition and oral dosage form of levodopa prodrug and method of use
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
JP2013523765A (en) 2010-04-01 2013-06-17 イデニク プハルマセウティカルス，インコーポレイテッド Compounds and pharmaceutical compositions for the treatment of viral infections
CN107050456B (en) 2010-09-28 2022-08-12 加利福尼亚大学董事会 GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US11154559B2 (en) 2011-09-29 2021-10-26 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
US8741882B2 (en) * 2012-01-20 2014-06-03 Sen Capital, Llc. Anti-diabetic compounds
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
ES2674704T3 (en) 2013-02-13 2018-07-03 Ark Diagnostics, Inc. Posaconazole Immunoassays
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
CA2966422C (en) 2014-10-31 2022-06-28 University Of Utah Research Foundation Compositions and methods for bile acid particles
US11040108B2 (en) 2016-04-29 2021-06-22 Brandeis University Amino acid- and peptide-steroid conjugates and use thereof
EP3826681A4 (en) * 2018-07-26 2022-08-17 Purdue Research Foundation Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy
US20230146782A1 (en) * 2019-08-06 2023-05-11 Du Jessica Xinyun Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
IT201900018110A1 (en) * 2019-10-07 2021-04-07 Dipharma Francis Srl SYNTHESIS OF GLYCOCONJUGATE DERIVATIVES OF A BILIARY ACID
CN118085007A (en) * 2020-04-28 2024-05-28 华东师范大学 Process for preparing cholic acid derivatives
KR102265708B1 (en) * 2021-03-19 2021-06-16 (주)프레이저테라퓨틱스 Amino acid derivatives, preparation method thereof and pharmaceutical composition for treatment of hepatitis B virus or D virus comprising the same
WO2022211481A1 (en) 2021-04-01 2022-10-06 에스엔제이 파마 인크 Oral nanoparticles for bioactive compound, and method of preparing same
CN114539343B (en) * 2022-03-10 2024-03-19 江苏东南纳米材料有限公司 Preparation method of glycocholic acid

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
DE1294961B (en) * 1963-03-21 1969-08-21 Merck Ag E Process for the preparation of 22-azacholestane derivatives and their acid addition salts
US4560512A (en) * 1982-09-30 1985-12-24 Merck & Co., Inc. Derivatives of steroid compounds linked to cyotoxic agents
JPS6253997A (en) * 1985-09-03 1987-03-09 Kowa Co Novel amino glycoside and pharmaceutical preparation containing same
DE3930696A1 (en) 1989-09-14 1991-03-28 Hoechst Ag GALLENSAEUREDERIVATE, METHOD FOR THE PRODUCTION THEREOF, USE AS MEDICAMENT
JPH0635472B2 (en) * 1990-06-28 1994-05-11 信 高橋 Diethylenetriamine triacetic acid oxyalkyl ester compounds and processes for their production
GB9212511D0 (en) 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5352682A (en) 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
SE9301916D0 (en) 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDES DERIVATIVES
NO940115D0 (en) 1994-01-13 1994-01-13 Nycomed Imaging As Contrast agents for X-ray and magnetic tomographic imaging
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5695738A (en) 1995-06-15 1997-12-09 Glycomed Incorporated Steroidal C-glycosides
US6288041B1 (en) * 1995-06-23 2001-09-11 Mitsubishi Chemical Corporation Sialic acid derivatives
JPH10114665A (en) * 1996-10-15 1998-05-06 Dokutaazu Kosumeteikusu:Kk Improver for aqueous body fluid and composition for oral administration comprising the same
JPH1160594A (en) 1997-08-25 1999-03-02 Sankyo Co Ltd Bile acid derivative
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
JP2003530329A (en) 2000-04-07 2003-10-14 ユニヴァーシティ オブ メリーランド，ボルチモア Bile acid-containing prodrugs with increased bioavailability
EP1361847A2 (en) * 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002243204A1 (en) * 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US6992076B2 (en) * 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
KR20090121404A (en) 2001-06-11 2009-11-25 제노포트 인코포레이티드 Prodrugs of gaba analogs, compositions and uses thereof
US7053076B2 (en) * 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs

Also Published As

Publication number Publication date
EP1358200A4 (en) 2005-07-20
WO2002028411A1 (en) 2002-04-11
WO2002044324A2 (en) 2002-06-06
US7678782B2 (en) 2010-03-16
US20070015716A1 (en) 2007-01-18
EP1358200A2 (en) 2003-11-05
US20020099041A1 (en) 2002-07-25
WO2002044324A3 (en) 2003-08-21
WO2002028883A1 (en) 2002-04-11
US7144877B2 (en) 2006-12-05

Similar Documents

Publication Publication Date Title
AU2002243204A1 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2002211863A1 (en) Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2001235691A1 (en) Use of paullone derivatives for making medicines
PL367180A1 (en) Stabilized oral pharmaceutical composition
AU6089200A (en) Rapid immediate release oral dosage form
AU2002332197A1 (en) Nicotine-containing film preparation
AU2177001A (en) Use of indirubine derivatives for making medicines
AU2002332713A1 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2002232468A1 (en) Pharmaceutical heterocyclic compounds
IL161348A (en) Substituted 4- phenyl-4-[1h - imidazol-2-yl] piperidine derivatives and their use for the preparation of pharmaceutical compositions
AU2002218502A1 (en) Lactam compounds and medicinal use thereof
AU2003276688A1 (en) Pharmaceutical composition of metaxalone with enhanced oral bioavailability
AU2001266081A1 (en) Improvement of itraconazole bioavailability
AU2001297611A1 (en) Pharmaceutical uses and synthesis of diketopiperazines
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2002251448A1 (en) Oral absorbed drugs
AU2001248943A1 (en) Pharmaceutical curative compound
AU2001292578A1 (en) Pharmaceutical compounds
HUP0101757A2 (en) Pharmaceutical uses for fluoroalkoxybenzyl-amino derivatives of nitrogen containing heterocycles
AU2001264900A1 (en) Pharmaceutical use of fibulin-1
AU2002348105A1 (en) Oral dosage forms for improving the bioavailability of therapeutic agents
AU2001276556A1 (en) Novel pharmaceutical use of quinnoline derivatives
AU2001292001A1 (en) Pharmaceutical oxan preparation
AU2001239349A1 (en) Oral pharmaceutical compositions containing n-sulphonylindoline derivatives
AU2001297710A1 (en) Integrated drug development techniques